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Abstract
Background: The purpose of the study was to determine the outcome of all patients with endometrial
adenocarcinoma cancer treated by laparoscopic hysterectomy at our institution, many of whom were
high-risk for surgery.
Methods: Data was collected by a retrospective search of the case notes and Electronic Patient Records
of the thirty eight patients who underwent laparoscopic hysterectomy for endometrial cancer at our
institutions.
Results: The median body mass index was 30 (range 19–67). Comorbidities were present in 76% (29
patients); 40% (15 patients) had a single comorbid condition, whilst 18% (7 patients) had two, and a further
18% (7 patients) had more than two. Lymphadenectomy was performed in 45% (17 patients), and lymph
node sampling in 21% (8 patients). Median operating time was 210 minutes (range 70–360 minutes).
Median estimated blood loss was 200 ml (range 50–1000 ml). There were no intraoperative complications.
Post-operative complications were seen in 21% (2 major, 6 minor). Blood transfusion was required in 5%
(2 patients). The median stay was 4 post-operative nights (range 1–25 nights). In those patients undergoing
lymphadenectomy, the mean number of nodes taken was fifteen (range 8–26 nodes). The pathological
staging was FIGO stage I 76% (29 patients), stage II 8% (3 patients), stage III 16% (6 patients). The
pathological grade was G1 31% (16 patients), G2 45% (17 patients), G3 24% (8 patients).
Conclusion: Laparoscopic hysterectomy can be safely carried out in patients at high risk for surgery, with
no compromise in terms of outcomes, whilst providing all the benefits inherent in minimal access surgery.
Background
The gold standard for staging and preliminary treatment
of endometrial cancer (EC) is surgical [1]. Surgery consists
of laparotomy, peritoneal washings, hysterectomy, bilat-
eral salpingo-oophorectomy, and pelvic lymphadenec-
tomy or sampling. The role of lymphadenectomy has
been dependant on histology, radiological findings, and
local policy.
Traditionally, surgical staging has been carried out
through laparotomy. In recent years several studies have
demonstrated that a laparoscopic approach to surgery for
EC results in outcomes comparable to or better than
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laparotomy [2-6]. The benefits of laparoscopic surgery for
EC may include reduced post-operative pain and analge-
sic requirements; earlier return of bowel function; shorter
hospital stay; and earlier return to daily activities [7-10].
Obese patients and those with medical comorbidities are
at greater risk of complications [11]. We describe our
experience of laparoscopic surgery for EC in a high risk
series of patients referred to a gynaecological cancer cen-
tre.
Methods
A retrospective search of the medical case notes and the
Electronic Patient Records provided the data. Besides
demographic statistics, patient details recorded included
parity, body mass index (BMI) and any comorbid condi-
tions. The type of operation, intra- and post-operative
complications and details of histopathological grade and
stage were also recorded.
All patients had pre-operative pelvic and abdominal CT or
MRI scan, and each case was discussed at a regular Multi-
Disciplinary Team Meeting. Operations were performed
by a gynaecological oncologist or a sub-specialty trainee
with the consultant in attendance. Histological reporting
included depth of myometrial invasion and nodal status.
A standard 4-port approach was employed. All patients
had peritoneal washing taken at the start of the procedure.
The policy is to perform laparoscopically assisted vaginal
hysterectomies. However, due to obesity and poor access
in this group of patients, this was not always possible. In
some cases the cervix was only visible with a hysteroscope;
in these women a laparoscopic total hysterectomy was
performed using a MacCartney tube. If there is macro-
scopic intraperitoneal disease, then our policy is to con-
vert to laparotomy.
Pelvic lymphadenectomy was performed in those who
were randomised to the ASTEC trial [12]. For those
patients who declined to enter the ASTEC trial, then all
those with stage Ic grade 3 cancers and above on radiolog-
ical and histopathological review underwent lym-
phadenectomy. Lymph node sampling was performed
instead of pelvic lymphadenectomy in cases with severe
co-morbidity, or not at all. By sampling we mean a limited
lymphadenectomy, without stripping the vessels. Para-
aortic lymphadenectomy for EC was not routinely per-
formed in this series.
Results
The median age was 62 years (range 38–82 years). The
average BMI was 31 (range 19–67). Nine patients (24%)
were nulliparous.
This group of patients had a number of comorbid condi-
tions; fifteen patients (40%) had a single comorbid condi-
tion, seven (18%) had two, and a further seven patients
(18%) had more than two.
Twenty four patients (63%) were overweight with a BMI
of 25 or more (table 1). Seventeen patients (45%) had a
BMI greater than 30. Hypertension was present in fifteen
patients (40%); eight patients (21%) had previous
intraabdominal pathology or surgery; and five patients
(13%) had cardiovascular disease (table 1). Other comor-
bidities included thyroid disease, breast cancer, throm-
boembolic disease, respiratory disease and diabetes
mellitus (table 1).
There were 27 (71%) laparoscopic-assisted vaginal hyster-
ectomies and 11 (29%) total laparoscopic hysterectomies.
Lymphadenectomy or lymph node sampling was per-
formed in 25 patients (66%). The median node count for
lymphadenectomy was 15 (range 8–26 nodes). Positive
nodes were found in four patients (11%), two who had
lymph node sampling and two who had lymphadenec-
tomy.
The surgical stage of the patients is shown in table 2.
Twelve patients (31%) had grade 1 disease, 17 (45%) had
grade 2 disease, and the remaining nine (24%) had grade
Table 1: Comorbid conditions
Comorbidity Patients
Overweight (BMI >25) 24 (63%)
Obese (BMI >30) 17 (45%)
Hypertension 15 (40%)
Severe endometriosis/previous peritonitis/previous abdominal surgery 8 (21%)
Cardiovascular disease 5 (13%)
Thyroid disease 4 (11%)
Breast cancer 5 (13%)
Thromboembolic disease 3 (8%)
Respiratory disease 3 (8%)
Diabetes mellitus 2 (5%)International Seminars in Surgical Oncology 2006, 3:28 http://www.issoonline.com/content/3/1/28
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three lesions. The pathological type was predominantly
endometrioid (table 3). Three patients (8%) had positive
peritoneal washings. Myometrial invasion and cervical
involvement are shown in table 4.
The median operative duration was 210 minutes (range
70–360 minutes). The median estimated blood loss was
200 ml (range 50–1000 ml). Blood transfusion was nec-
essary in two patients (5%). None of the laparoscopic
cases needed to be converted into open procedures and
there were no incidents of intra-operative visceral damage.
The median length of stay was four post-operative nights
(range 1 – 25 nights).
There were a total of eight post-operative complications,
two of which were major (table 5).
Discussion
This series of patients had a large number of comorbidi-
ties, particularly with regard to obesity. It might be
expected that these patients would have more intra-oper-
ative complications (due to difficulties with access) and
more post-operative complications (due to comorbid
conditions) than patients with fewer risk factors for sur-
gery. Here we have demonstrated that this is not the case.
These results show that EC patients perceived to be poor
risk for a major surgical procedure can be safely staged
using laparoscopic methods. It has been shown that obese
patients with EC can benefit from surgery via the laparo-
scopic route compared with laparotomy in terms of a
reduced blood loss, less post-operative pain and a shorter
hospital stay [13]. A recent small audit of 4 morbidly
obese (BMI >40) women found that laparoscopic total
hysterectomy was safe in these patients [14].
With regard to other published series of EC patients oper-
ated on laparoscopically, our data compare favourably in
terms of post-operative complications, intra-operative
blood loss, duration of surgery, and length of post-opera-
tive stay [7,13,15]. The two major post-operative compli-
cations seen here (renal failure secondary to diclofenac
use and an infected lymphocyst) were both successfully
managed conservatively. The safety and feasibility of
laparoscopic hysterectomy in this group of high-risk
patients is demonstrated by the zero conversion to
laparotomy, and the absence of intraoperative complica-
tions. Postoperative blood transfusion was minimal, and
where blood loss was greater than 300 ml, this invariably
occurred in the vaginal part of the hysterectomy.
Lymph node counts following pelvic lymphadenectomy
were similar to those seen in other studies utilising the
laparoscopic approach [7,13,15]. Lymph node sampling
was performed in patients in whom a shorter anaesthetic
was desirable. With increasing experience of laparoscopic
techniques, operating times will be further reduced. In
any case, all patients with positive lymph nodes following
either sampling or pelvic lymphadenectomy are offered
adjuvant, extended field radiotherapy. The role of lym-
phadenectomy in women with endometrial cancer will
become clearer when the results of the ASTEC study [12]
are reported.
We believe our study is important, as obesity is a growing
epidemic in the UK and other developed nations. It has
been shown that a cohort of obese patients with EC have
a greater risk of hypertension, diabetes and pulmonary
disease than patients with EC who are not obese [16]. As
we see more and more obese patients in our clinics, the
challenge to gynaecologists and anaesthetists in treating
these patients with multiple medical co-morbidities is
increasing.
These data are limited by patient numbers. Now that a
laparoscopic approach is established in the staging and
primary treatment of EC, we can continue to build on our
early experience.
Table 3: Pathological type
Pathological type Patients
Endometrioid 30 (79%)
Serous papillary 3 (8%)
Clear cell/mixed mullerian/mixed endometrioid +serous papillary/mixed serous papillary + clear cell/intraepithelial 5 (13%)
Table 2: FIGO stage on final histology
Stage Sub-stage
I 29 (76%) Ia 11 (29%)
Ib 14 (37%)
Ic 4 (11%)
II 3 (8%) IIa 1 (2%)
IIb 2 (5%)
III 6 (16%) IIIa 2 (5%)
IIIb 0
IIIc 4 (11%)
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Conclusion
Women with EC are often high-risk surgical candidates.
Laparoscopic hysterectomy can be safely carried out in
these patients with no compromise in terms of outcomes,
whilst providing all the benefits inherent in minimal
access surgery.
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Table 4: Myometrial and cervical involvement
Myometrial invasion Patients
None 9 (24%)
<50% 16 (42%)
>50% 13 (34%)
Cervical involvement
Stromal 2 (5%)
Glandular 1 (2%)
Table 5: Post-operative complications
Major complications Patients
Renal failure secondary to 
diclofenac use (reversible)
1
Infected lymphocyst 1
Minor complications
Unexplained vomiting 1
Superficial umbilical wound 
breakdown
1
Extensive bruising of anterior 
abdominal wall
1
Pyrexia of unknown origin 3